How Maois Intensify Tryptamine Mushroom Experiences

Tryptamines are hallucinogens that are often ingested with monoamine oxidase inhibitors (MAOIs). MAOIs are known to potentiate the effects of tryptamines. MAOIs are found in plants such as Peganum and Banisteriopsis and fungi such as Cordyceps. MAOIs have also been found in magic mushrooms, specifically the Psilocybe mushroom. MAOIs inhibit the breakdown of dimethyltryptamine (DMT) in the body, thereby potentiating its effects. MAOIs are also expected to potentiate the effects of psilocybin, which is the compound responsible for the psychotropic effects of magic mushrooms.

MAOIs and psilocybin mushrooms

MAOIs, or monoamine oxidase inhibitors, are molecules that inhibit monoamine oxidase (MAO) and have been found in "magic" mushrooms of the Psilocybe genus. MAOs are enzymes responsible for breaking down compounds such as psilocybin, psilocin, and DMT, rendering them inactive. By inhibiting MAOs, MAOIs can potentiate the effects of these compounds, leading to enhanced psychoactive and hallucinogenic experiences.

Psilocybe mushrooms, considered sacred by ancient cultures such as the Aztecs, produce a range of metabolites, including psilocybin, psilocin, and β-carbolines. β-carbolines, such as harmane and harmine, are a class of compounds that act as potent MAO inhibitors. The simultaneous presence of psilocybin and β-carbolines in these mushrooms creates a synergistic effect, with the β-carbolines interfering with the degradation of psilocybin and thus prolonging and enhancing its psychotropic effects.

The discovery of MAOIs in Psilocybe mushrooms is significant as it provides insights into the complex chemistry and pharmacology of these fungi. While psilocybin has been the primary focus of psychedelic research, the presence of additional compounds and their synergistic interactions contribute to the overall psychedelic experience. This is known as the entourage effect, where the combination of compounds produces effects greater than the sum of their individual parts.

MAOIs have also been found in other natural sources, such as ayahuasca, a hallucinogenic beverage used in traditional South American cultures. Ayahuasca contains DMT, which is typically inactive when ingested orally due to first-pass metabolism. However, the β-carbolines in ayahuasca block the breakdown of DMT in the gastrointestinal tract, allowing it to become orally active and contributing to its hallucinogenic effects.

While the combination of MAOIs and tryptamine hallucinogens like psilocybin mushrooms can lead to enhanced psychoactive experiences, there is still relatively little known about the consequences of their combined use. Further research is needed to fully understand the interactions between MAOIs and psilocybin and their potential risks and benefits.

MAOIs and serotonin

MAOIs, or monoamine oxidase inhibitors, are a separate class of antidepressants that treat nervous system disorders such as panic disorder, social phobia, and atypical depression. They are not the first choice in treating mental health disorders due to several dietary restrictions, side effects, and safety concerns. MAOIs are only a treatment option when all other medications are unsuccessful.

Serotonin is a substrate of MAO A, and MAOIs can prevent the breakdown of serotonin in the body. Serotonin syndrome is a potentially fatal drug reaction that results from having too much serotonin in the body. It is rare, but it can happen when you take a new MAOI, increase your dose, or take it in combination with other medications that increase serotonin levels, such as SSRIs or opioids like tramadol and methadone. Symptoms of serotonin syndrome include nervousness, nausea, vomiting, dilated pupils, muscle twitching, involuntary contractions, spasms, rigidity, sweating, shivering, confusion, delirium, rapid heart rate, high blood pressure, and loss of consciousness. If left untreated, serotonin syndrome can be fatal.

MAOIs have been found in "magic" Psilocybe mushrooms, which produce an ayahuasca-like set of metabolites that may impact the onset and duration of their effects. The psychotropic effects of these mushrooms are caused by the l-tryptophan-derived alkaloid psilocybin, which interferes with serotonergic neurotransmission by acting as a partial agonist on the 5-hydroxytryptamine (5-HT)2A-receptor. The effects of psilocybin include synesthesia, visual hallucinations, dilated pupils, and more.

Tryptamine hallucinogens are often ingested together with MAOIs, and there is evidence that the two are abused together. The ayahuasca brew, for example, combines chacruna (Psychotria viridis), which delivers an extra dose of the tryptamine hallucinogen DMT, and ayahuasca (Banisteriopsis caapi), which contains MAOIs. The MAOIs in ayahuasca inhibit the breakdown of DMT in the gastrointestinal tract, allowing it to have psychoactive effects.

MAOIs might be a master potentiator of psilocybin, as they are expected to potentiate the effects of psilocybin through the entourage effect. However, few scientific studies have looked at the entourage effect in psychedelic mushrooms, and more research is needed to fully understand the active ingredients they contain.

MAOIs and dopamine

MAOIs, or monoamine oxidase inhibitors, are molecules found in psychedelic mushrooms that are responsible for the effects of the psychedelics. They inhibit the breakdown of dimethyltryptamine (DMT), a potent hallucinogen. MAOIs are also known as carbolines.

MAOIs were discovered in the 1950s and were the first class of medication used to treat unipolar depression. They are used as antidepressants and potently inhibit at least the A isoforms of monoamine oxidase (MAO). MAO is an enzyme that catalyzes the oxidative deamination of monoamines, and two isoforms of this enzyme have been identified in the mammalian brain: MAOA and MAOB. MAOA is responsible for the metabolization of serotonin (5-HT) and norepinephrine (NE), while MAOB metabolizes phenylethylamine and histamine. Dopamine (DA) and tyramine are common substrates for both subtypes.

Long-term administration of MAOIs alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Specifically, the MAOI clorgyline decreases the firing rate of 5-HT and NE neurons, with only 5-HT neurons recovering after prolonged administration, attributed to the desensitization of cell body 5-HT1A autoreceptors. This increase in tissue and extracellular levels of 5-HT and NE in various brain areas is also seen with the pharmacological inhibition of MAOA.

MAO-A and MAO-B have different roles, with MAO-A regulating dopamine levels and MAO-B controlling tonic GABA levels. Inhibition of MAO-A increases the level of 5-MeO-DMT in plasma and the whole brain, altering 5-MeO-DMT pharmacodynamics by increasing its accumulation in the central nervous system.

MAOIs and adrenaline

MAOIs, or monoamine oxidase inhibitors, are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are known to be effective antidepressants, especially for treatment-resistant depression and atypical depression. They are also used to treat various other disorders, including panic disorder, social anxiety disorder, Parkinson's disease, and several others.

The use of adrenaline (epinephrine) in the context of concurrent MAOI use has been a subject of uncertainty. MAOIs may potentiate or alter the action of several drugs, and certain foods. Indirectly acting sympathomimetic amines, such as amphetamines, ephedrine, and MAOI with amphetamine-like properties, can be potentiated. This is because they may release increased amounts of noradrenaline from sympathetic nerve endings after MAO inhibition. MAOIs can also cause an impaired metabolism of circulating amines, leading to augmented and prolonged effects in patients treated with MAOI.

The interaction between MAOIs and adrenaline is complex and not fully understood. However, it is known that MAOIs can alter the pharmacodynamics of certain compounds by increasing their accumulation in the central nervous system. In the case of adrenaline, MAOIs may affect its metabolism and accumulation, potentially leading to prolonged or enhanced effects.

The concurrent use of MAOIs and adrenaline requires caution due to the potential for adverse reactions. It is recommended that the adrenaline dosage be reduced by 75% and the duration extended when used in combination with MAOIs. This is to avoid the risk of a hypertensive crisis, which can occur due to increased concentrations of tyramine in blood plasma, causing the release of norepinephrine and the constriction of blood vessels.

The discovery of MAOIs in psychedelic mushrooms, such as Psilocybe mushrooms, has added a new dimension to the understanding of their psychotropic effects. The mushrooms produce an ayahuasca-like set of metabolites, including MAO inhibitors, that may impact the onset and duration of their effects. MAOIs in these mushrooms can inhibit the breakdown of psilocybin, psilocin, and DMT, potentiating their psychoactive effects.

MAOIs and ayahuasca

Ayahuasca is a traditional South American psychoactive decoction made from the Banisteriopsis caapi vine and a dimethyltryptamine (DMT)-containing plant. Ayahuasca is used by Indigenous cultures in the Amazon and Orinoco basins as part of traditional medicine and shamanism. The name "ayahuasca" means "spirit rope" or "liana of the soul" in the Quechuan languages spoken in the Andes.

The ayahuasca brew combines chacruna (Psychotria viridis), which delivers an extra dose of DMT, and ayahuasca (Banisteriopsis caapi). Ayahuasca contains β-carbolines such as harmaline and harmine, which are reversible monoamine oxidase inhibitors (MAOIs). MAOIs prevent the breakdown of DMT in the body, which is normally inactive when ingested orally due to first-pass metabolism. By inhibiting the breakdown of DMT, MAOIs potentiate the effects of ayahuasca.

MAOIs have also been found in "magic" Psilocybe mushrooms, which produce an ayahuasca-like set of metabolites. The β-carbolines produced by these mushrooms are potent inhibitors of monoamine oxidases, which interfere with psilocybin degradation and contribute to the mushrooms' psychotropic effects.

It is not uncommon for tryptamine hallucinogens like ayahuasca to be administered in combination with MAOIs. The combination of MAOIs and tryptamine hallucinogens has been studied in rats, and the results indicate that MAOIs alter tryptamine pharmacodynamics by increasing its accumulation in the central nervous system. However, relatively little is known about the consequences of their combined use in humans.

Frequently asked questions